Fasinumab - CAS 1190239-42-9

Fasinumab (Anti-Human NGF), a human IgG1κ monoclonal antibody targeting nerve growth factor (NGF), can be used in studies about acute sciatica and knee osteoarthritis (OA) . clinical research has demonstrated that Fasinumab achieves statistically significant improvements in both pain and physical function scores when compared to a placebo control group.

Trk receptor

Tyrosine Kinase/Adaptors

1190188

0.997

-20°C

Ice Packs

Inhibitory Antibodies